SCHEMBL2598265

SCHEMBL2598265

CCC(=O)NC(c1ccc(F)cc1)c1cc(Cl)c2cccnc2c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALOX12 P18054 9/20 1.00
KDM4E B2RXH2 9/20 1.00
L3MBTL1 Q9Y468 3/20 0.83
NPC1 O15118 7/20 0.73
RAB9A P51151 7/20 0.73
MEN1 O00255 2/20 0.73
KMT2A Q03164 2/20 0.73
HTT P42858 1/20 0.73
POLB P06746 2/20 0.71
LMNA P02545 2/20 0.71
SMN1; SMN2 Q16637 2/20 0.71
TDP1 Q9NUW8 2/20 0.71
HSP90AA1 P07900 4/20 0.68
KDM1A O60341 1/20 0.68
ADAMTS5 Q9UNA0 2/20 0.66
MITF O75030 1/20 0.64
MCL1 Q07820 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23792596 0.92 ALOX12 (0.86) ALOX12KDM4EL3MBTL1NPC1RAB9A
SCHEMBL2153066 0.92 ALOX12 (0.86) ALOX12KDM4EL3MBTL1NPC1RAB9A
SCHEMBL2598275 0.91 KDM4E (1.00) ALOX12KDM4EL3MBTL1NPC1RAB9A
SCHEMBL609006 0.88 ADAMTS5 (0.84) ALOX12KDM4EL3MBTL1NPC1RAB9A
SCHEMBL1814805 0.87 KDM4E (0.78) ALOX12KDM4EL3MBTL1NPC1RAB9A
SCHEMBL30876646 0.86 ALOX12 (0.77) ALOX12KDM4EL3MBTL1NPC1RAB9A
SCHEMBL24634616 0.86 ALOX12 (0.77) ALOX12KDM4EL3MBTL1NPC1RAB9A
SCHEMBL1813430 0.86 ADAMTS5 (0.88) ALOX12KDM4EADAMTS5
SCHEMBL2153092 0.85 KDM1A (0.81) ALOX12KDM4EL3MBTL1NPC1RAB9A
SCHEMBL30876565 0.85 KDM1A (0.81) ALOX12KDM4EL3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130096159-A1 INHIBITORS OF HUMAN 12-LIPOXYGENASE The United States of America, as represented the Secretary Department of Health & Human Service (US) 2013-04-18 US claimed
EP-2571853-A1 INHIBITORS OF HUMAN 12-LIPOXYGENASE The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) 2013-03-27 EP claimed
WO-2011146618-A1 INHIBITORS OF HUMAN 12-LIPOXYGENASE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2011-11-24 WO claimed
US-20130096159-A1 INHIBITORS OF HUMAN 12-LIPOXYGENASE The United States of America, as represented the Secretary Department of Health & Human Service (US) 2013-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096159-A1 INHIBITORS OF HUMAN 12-LIPOXYGENASE ALOX12, ALOX15B, ALOX15 ALOX12 1/4885KDM4E 2798/4885L3MBTL1 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.